For the Inventor, By the Inventor

Enter assignee name

Marlborough, MA, United States of America

Rxi Pharmaceuticals Corporation

USPTO Granted Patents = 16

EPO Patents = 3

Forward Citations = 656

Loading Chart...

Loading Chart...

10 inventors (with patents filed for the assignee):

Joanne Kamens (15 out of 30 patents)

Anastasia Khvorova (15 out of 202 patents)

Tod M Woolf (14 out of 50 patents)

4. William Salomon (13 out of 28 patents)

5. Dmitry Samarsky (11 out of 22 patents)

6. James Cardia (9 out of 22 patents)

7. Pamela A Pavco (6 out of 13 patents)

8. Karen G Bulock (3 out of 8 patents)

9. Lyn Libertine (3 out of 8 patents)

10. Michelle Miller (1 out of 2 patents)

11. William R Levis (4 patents)

12. Leonard L Kaplan (6 patents)

13. John G Callahan (1 patent)

16 patents: Sort by Forward Citations

1. 10167471 - Inhibition of PCSK9 through RNAI (2019-01-01),

2. 10138485 - Neutral nanotransporters (2018-11-27),

3. 10131904 - Modified RNAi polynucleotides and uses thereof (2018-11-20),

4. 10041073 - Reduced size self-delivering RNAi compounds (2018-08-07),

5. 9963702 - RNA interference in dermal and fibrotic indications (2018-05-08),

6. 9938530 - RNA interference in skin indications (2018-04-10),

7. 9745574 - RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality (2017-08-29),

8. 9493774 - Inhibition of PCSK9 through RNAi (2016-11-15),

9. 9340786 - RNA interference in dermal and fibrotic indications (2016-05-17),

10. 9303259 - RNA interference in skin indications (2016-04-05),

11. 9175289 - Reduced size self-delivering RNAi compounds (2015-11-03),

12. 9095504 - RNA interference in ocular indications (2015-08-04),

13. 9074211 - Inhibition of MAP4K4 through RNAI (2015-07-07),

14. 8815818 - Phagocytic cell delivery of RNAI (2014-08-26),

15. 8796443 - Reduced size self-delivering RNAi compounds (2014-08-05),

RXi Pharmaceuticals Corporation is a biotechnology company focused on developing innovative RNAi-based therapeutics. Using its proprietary self-delivering RNAi (sd-rxRNA) technology platform, RXi aims to develop the next generation of RNAi therapy targeting a wide range of diseases. The company's sd-rxRNA compounds are designed to selectively silence disease-causing genes, offering potential treatment options for various conditions including cancer, dermatology disorders, and ophthalmology disorders.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

16 Patents

#32 in Marlborough, MA

#1,160 in Massachusetts

#19,269 in US

#36,651 in the World

Marlborough, MA, United States of America

Rxi Pharmaceuticals Corporation

Forward Citations = 656

10 inventors:

Joanne Kamens (15 out of 30 patents)

Anastasia Khvorova (15 out of 202 patents)

Tod M Woolf (14 out of 50 patents)

4. William Salomon (13 out of 28 patents)

5. Dmitry Samarsky (11 out of 22 patents)

Please report any incorrect information to support@idiyas.com

Loading…